Vonicog alfa, sold under the brand names Vonvendi and Veyvondi, is a medication used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder). [6] [5] [7] [8] It is a recombinant von Willebrand factor. [6] [5] The most common adverse reactions are generalized itching, vomiting, nausea, dizziness, and vertigo. [6]

Veyvondi is a medicine used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder) who cannot be treated with desmopressin (another medicine to stop bleedings) or in whom desmopressin does not work.

VEYVONDI should be administered with recombinant factor VIII if the FVIII:C levels are < 40%, or are unknown, to control bleeding. The rFVIII dose should be calculated according to the difference

VEYVONDI is used to prevent and treat bleeding episodes, including bleeding during surgery in adult patients (aged 18 years and older) with von Willebrand disease. It is used when treatment with another medicine, desmopressin, is not effective or cannot be given.

Veyvondi is a medicine used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder) who cannot be treated with desmopressin (another medicine to stop bleedings) or in whom desmopressin does not work. It is used to prevent and treat bleeding episodes, including during surgery.

VEYVONDI is a recombinant human von Willebrand factor (rVWF). VEYVONDI behaves in the same way as endogenous von Willebrand factor. Administration of VEYVONDI allows correction of the haemostatic abnormalities exhibited by patients who suffer from von Willebrand factor deficiency (von Willebrand's disease) at two levels:

2018年7月6日 · 如果获批，Veyvondi将成为欧洲首个也是唯一一个治疗VWD的rVWF药物，专门解决VWF的原发性缺陷或功能障碍，同时使身体恢复或维持足够的因子VIII（FVIII）血浆水平。

2018年9月18日 · PMLiVE 于 9 月 13 日报道，欧盟委员会批准夏尔（Shire）止血药物 Veyvondi，其旨在血管性血友病（VWD）成人患者中用于预防手术出血。 该药物以注射剂使用，目前它是欧洲获批的首个也是唯一的一个重组血管性血友病因子（rVWF）药物，专门用于治疗原发性血管性血友病因子缺乏，血管性血友病因子是血液中所必需的促使血液正常凝固的几种蛋白质类型之一。 血管性血友病患者通常缺乏这种蛋白质，受此影响的患者有流鼻血，牙龈出 …

2017年6月29日 · Veyvondi 是一种 VWF 替代疗法，其不添加任何人类或动物来源的外源性原料，所以这款产品只含有微量的 FVIII。「从临床特征及生理学来说，Veyvondi 是该类血管性血友病治疗药物中的首款药物，」Shire 全球医疗事务总监 Dietrich 称。

Vonvendi（血管假性血友病因子 [重组体]）用于18岁及以上年龄的血管性血友病患者。 Vonvendi 是首款获FDA批准的重组血管假性血友病因子，在确诊患有血管性血友病的成年患者中，该药物被批准用于出血发作的按需治疗及控制。 Vonvendi 是血液中的一种天然蛋白质，有助于血液凝固。 患有称为 von Willebrand 病的遗传性凝血障碍的人血液中没有足够的这种蛋白质。 von Willebrand 因子缺乏会导致不受控制的出血。 Vonvendi 用于 18 岁及以上的成人，这些成人被诊断为 …